Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Clinical Trials as Topic
Drug Resistance, Neoplasm
/ genetics
Fusion Proteins, bcr-abl
/ genetics
Humans
Imidazoles
/ adverse effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Leukemia, Myeloid, Chronic-Phase
/ drug therapy
Protein Kinase Inhibitors
/ adverse effects
Pyridazines
/ adverse effects
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
05
08
2022
received:
29
06
2022
accepted:
10
08
2022
pubmed:
3
9
2022
medline:
13
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Ponatinib, the only third-generation pan-BCR::ABL1 inhibitor with activity against all known BCR::ABL1 mutations including T315I, has demonstrated deep and durable responses in patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior second-generation (2G) TKI treatment. We present efficacy and safety outcomes from the Ponatinib Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and CML Evaluation (PACE) and Optimizing Ponatinib Treatment in CP-CML (OPTIC) trials for this patient population. PACE (NCT01207440) evaluated ponatinib 45 mg/day in CML patients with resistance to prior TKI or T315I. In OPTIC (NCT02467270), patients with CP-CML and resistance to ≥2 prior TKIs or T315I receiving 45 or 30 mg/day reduced their doses to 15 mg/day upon achieving ≤1% BCR::ABL1
Identifiants
pubmed: 36054756
doi: 10.1002/ajh.26686
pmc: PMC9804741
doi:
Substances chimiques
Imidazoles
0
Protein Kinase Inhibitors
0
Pyridazines
0
ponatinib
4340891KFS
Fusion Proteins, bcr-abl
EC 2.7.10.2
Banques de données
ClinicalTrials.gov
['NCT02467270', 'NCT01207440']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1419-1426Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : This study is sponsored by Takeda Development Center Americas, Inc.
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Am J Hematol. 2022 Nov;97(11):1419-1426
pubmed: 36054756
Blood. 2021 Nov 25;138(21):2031-2041
pubmed: 34407542
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Haematologica. 2013 Oct;98(10):1510-6
pubmed: 23716543
Blood. 2018 Jul 26;132(4):393-404
pubmed: 29567798
Blood. 2014 Feb 27;123(9):1309-18
pubmed: 24345751
Ann Intern Med. 2015 Sep 15;163(6):461-4
pubmed: 26259067
Am J Hematol. 2020 Jun;95(6):691-709
pubmed: 32239758
Leukemia. 2021 Feb;35(2):440-453
pubmed: 33414482
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
Br J Haematol. 2015 Jan;168(1):69-81
pubmed: 25196702
Am J Hematol. 2016 Feb;91(2):252-65
pubmed: 26799612
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Blood. 2021 Nov 25;138(21):2042-2050
pubmed: 34407543
Blood. 2009 Nov 12;114(20):4361-8
pubmed: 19729517
Leukemia. 2010 Jul;24(7):1299-301
pubmed: 20520639
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
Cancer Res. 2004 Jan 15;64(2):672-7
pubmed: 14744784
Leuk Res. 2015 Jan;39(1):58-64
pubmed: 25466286
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
Blood. 2007 Oct 1;110(7):2242-9
pubmed: 17496200
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448